Clinical Trial

Real-world Data in Patients With Breast Cancer Treated With Abemaciclib

Study acronym: ENDURANCE
Recruiting
View on ClinicalTrials.gov →
Summary
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-07-26; most recent amendment 2026-07-20.
Trial Details
NCT Number NCT04985058
Lead Sponsor Hellenic Cooperative Oncology Group
Conditions Breast Cancer
Enrollment 108 participants
Start Date 2021-10-06
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-21